Back to search

Article

Neoadjuvant Vidutolimod and Nivolumab in High-Risk Resectable Melanoma

2022-11-08

Abstract excerpt

<title>Abstract</title> <p>Intratumoral TLR9 agonists and anti-PD-1 provide durable clinical responses and broad immune activation. To evaluate efficacy and mechanisms of action of this combined treatment, we conducted a single-arm phase 2 neoadjuvant study of TLR9 agonist vidutolimod combined with anti-PD-1 nivolumab (vidu/nivo) in patients with high-risk resectable melanoma. In 30 evaluable patients, 57% (17/30...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
e089a35f-0ad4-5bff-b2fc-134011762526
DOI
10.21203/rs.3.rs-2235839/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Neoadjuvant Vidutolimod and Nivolumab in High-Risk Resectable MelanomaDOI 10.21203/rs.3.rs-2235839/v1
Long-term survival after neoadjuvant low-dose ipilimumab plus high-dose nivolumab in resectable stage III melanoma: the 5-year survival-update and biomarker analysis from the PRADO-trialSemantic proximity
Bacteroides vulgatus and Bacteroides dorei predict immune-related adverse events in immune checkpoint blockade treatment of metastatic melanomaSemantic proximity
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockadeSemantic proximity
Multi-omics Profiling of Patients with Melanoma Treated with Nivolumab in Project HOPE.Semantic proximity
The tumor microbiome as a predictor of outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitorsSemantic proximity
Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06).Semantic proximity
Dendritic cell effector mechanisms and tumor immune microenvironment infiltration define TLR8 modulation and PD-1 blockadeSemantic proximity
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of responseSemantic proximity
Melanoma patient response to nivolumab treatment for metastatic lung lesions: Multi-OMICS analysis in Project HOPE.Semantic proximity
Association of gut microbiota and immune gene expression with response to targeted therapy in BRAF mutated melanomaSemantic proximity
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.Semantic proximity
Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 studySemantic proximity
Select a neighboring publication to make it the new centre.